SCHEMBL3768073

SCHEMBL3768073

O=C(CN1CCN(c2ccc(-c3ccccc3C(F)(F)F)nn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.50
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
KDM2B Q8NHM5 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
SCD O00767 6/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PARP1 P09874 1/20 0.40
MAPT P10636 1/20 0.39
WNT3A P56704 1/20 0.39
DCTPP1 Q9H773 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773946 0.88 IL4I1 (0.43) ALDH1A1KDM4EKDM2BHRH3PARP1
SCHEMBL3769132 0.87 ALDH1A1 (0.43) ALDH1A1KDM4EKDM2BHRH3CYP1A2
SCHEMBL3767828 0.85 HRH3 (0.40) ALDH1A1KDM4EHRH3PARP1MAPT
SCHEMBL3773927 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EHRH3SMN1; SMN2PARP1
SCHEMBL3777144 0.84 HRH3 (0.42) ALDH1A1KDM4EHRH3PARP1MAPT
SCHEMBL3774737 0.84 HRH3 (0.50) CNR2ALDH1A1KDM4EKDM2BHRH3
SCHEMBL3777001 0.84 LMNA (0.44) ALDH1A1KDM2BHRH3SCDSMN1; SMN2
SCHEMBL3776065 0.83 MEN1 (0.47) CNR2ALDH1A1HRH3SCDSMN1; SMN2
SCHEMBL3774007 0.83 CNR2 (0.54) CNR2ALDH1A1KDM4EKDM2BHRH3
SCHEMBL3770268 0.82 HRH3 (0.44) CNR2ALDH1A1KDM4EHRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CNR2 47/4885ALDH1A1 1210/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.